PMID- 31766782
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2079-6382 (Print)
IS  - 2079-6382 (Electronic)
IS  - 2079-6382 (Linking)
VI  - 8
IP  - 4
DP  - 2019 Nov 22
TI  - Novel Tetracyclines Versus Alternative Antibiotics for Treating Acute Bacterial 
      Infection: A Meta-Analysis of Randomized Controlled Trials.
LID - 10.3390/antibiotics8040233 [doi]
LID - 233
AB  - This meta-analysis assessed the efficacy and safety of novel tetracyclines for 
      treating acute bacterial infections. Data from PubMed, Web of Science, EBSCO, 
      Cochrane databases, Ovid Medline, and Embase databases were accessed until 11 
      July 2019. Only randomized controlled trials (RCTs) comparing the efficacy of 
      novel tetracyclines with that of other antibiotics for treating acute bacterial 
      infections were included. Primary outcomes included the clinical response, 
      microbiological response, and risk of adverse events (AEs). A total of eight RCTs 
      were included, involving 2283 and 2197 patients who received novel tetracyclines 
      and comparators, respectively. Overall, no significant difference was observed in 
      the clinical response rate at test of cure between the experimental and control 
      groups (for modified intent-to-treat [MITT] population, risk ratio [RR]: 1.02, 
      95% confidence interval [CI]: 0.99-1.05; for clinically evaluable [CE] 
      population, RR: 1.02, 95% CI: 1.00-1.04; and for microbiological evaluable [ME] 
      population, RR: 1.01, 95% CI: 0.99-1.04). No significant difference in the 
      microbiological response at the end of treatment was observed between the 
      experimental and control groups (for ME population, RR: 1.01, 95% CI: 0.99-1.03; 
      for microbiological MITT population, RR: 1.01, 95% CI: 0.96-1.07). No difference 
      was observed concerning the risk of treatment-emergent adverse events (TEAEs), 
      serious adverse events, and discontinuation of treatment due to TEAEs and 
      all-cause mortality between the two groups. In conclusion, clinical efficacy and 
      safety profile for novel tetracyclines in the treatment of acute bacterial 
      infections were found to be similar to those for other available antibiotics.
FAU - Lan, Shao-Huan
AU  - Lan SH
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian 351100, China.
FAU - Lin, Wei-Ting
AU  - Lin WT
AD  - Department of Orthopedic, Chi Mei Medical Center, Tainan 71004, Taiwan.
AD  - Department of Physical Therapy, Shu Zen Junior College of Medicine and 
      Management, Kaohsiung 82144, Taiwan.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Yijia Pharmacy, Tainan 70846, Taiwan.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, Putian 351100, China.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan 71051, Taiwan.
FAU - Wang, Jui-Hsiang
AU  - Wang JH
AD  - Department of Internal Medicine, Division of Infection Disease, Kaohsiung 
      Veterans General Hospital, Tainan Branch, Tainan 71051, Taiwan.
FAU - Chao, Chien-Ming
AU  - Chao CM
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20191122
PL  - Switzerland
TA  - Antibiotics (Basel)
JT  - Antibiotics (Basel, Switzerland)
JID - 101637404
PMC - PMC6963300
OTO - NOTNLM
OT  - acute bacterial infection
OT  - eravacycline
OT  - novel tetracycline
OT  - omadacycline
COIS- The authors declare no conflict of interest.
EDAT- 2019/11/27 06:00
MHDA- 2019/11/27 06:01
PMCR- 2019/11/22
CRDT- 2019/11/27 06:00
PHST- 2019/10/05 00:00 [received]
PHST- 2019/11/14 00:00 [revised]
PHST- 2019/11/21 00:00 [accepted]
PHST- 2019/11/27 06:00 [entrez]
PHST- 2019/11/27 06:00 [pubmed]
PHST- 2019/11/27 06:01 [medline]
PHST- 2019/11/22 00:00 [pmc-release]
AID - antibiotics8040233 [pii]
AID - antibiotics-08-00233 [pii]
AID - 10.3390/antibiotics8040233 [doi]
PST - epublish
SO  - Antibiotics (Basel). 2019 Nov 22;8(4):233. doi: 10.3390/antibiotics8040233.